227023-66-7Relevant articles and documents
Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors
Groebke Zbinden, Katrin,Banner, David W.,Ackermann, Jean,D'Arcy, Allan,Kirchhofer, Daniel,Ji, Yu-Hua,Tschopp, Thomas B.,Wallbaum, Sabine,Weber, Lutz
, p. 817 - 822 (2007/10/03)
Proof of concept experiments have shown that tissue factor/factor VIIa inhibitors have antithrombotic activity without enhancing bleeding propensity. Starting from lead compounds generated by a biased combinatorial approach, phenylglycine amide tissue fac
Serine protease inhibitors
-
, (2008/06/13)
Compounds having the structure shown below wherein A, B, N1, N2, X, Y, Q, R2, R5and R6are as defined herein are useful to inhibit serine protease enzymes, such as TF/factor VIIa factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
N-(4-carb-amimidophenyl)glycineamide derivatives
-
, (2008/06/13)
N-(4-carbamimidophenylamino) phenylglycineamide derivative compounds having the formula: in which E, g1, g2, Q, R and X1 to X4 are each as defined in the description, and hydrates or solvates and physiologically acceptable salts thereof can be used as inhibitors of the formation of the coagulation factors Xa, IXa and thrombin induced by the factor VIIa and by the tissue factor. These compounds can be used as medicaments for the treatment and/or prevention of thromboses, apoplexy, cardiac infarction, inflammation and arteriosclerosis or as antitumor agents.